AAX Biotech

About:

Technologies for the next generation of antibody therapies.

Website: https://aaxbiotech.com

Top Investors: Phase2Phase Biopharma, Northislet, Life Science Invest, Karolinska Institutet Holding, HJKK Didrikson

Description:

AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.